Show simple item record

dc.contributor.advisorMabandla, Musa Vuyisile.
dc.contributor.advisorChiliza, Bonginkosi.
dc.creatorNdlangisa, Ziyanda Lynn.
dc.date.accessioned2020-09-10T15:33:30Z
dc.date.available2020-09-10T15:33:30Z
dc.date.created2019
dc.date.issued2019
dc.identifier.urihttps://researchspace.ukzn.ac.za/handle/10413/18656
dc.descriptionMasters Degree. University of KwaZulu-Natal, Durban.en_US
dc.description.abstractBackground: The introduction of antipsychotics has been a significant milestone in the treatment of schizophrenia. However, these agents have several important side effects, such as metabolic syndrome. Options to curb these side effects include a change in the treatment option, changes in patients’ lifestyle, and the addition of other medications such as metformin, among others. Thus, this study investigated whether dose reduction of an injectable antipsychotic, flupenthixol decanoate, would result in improvement of metabolic syndrome parameters in a cohort of first-episode schizophrenia patients in South Africa. Methods: The study included 33 participants recruited at the Tygerberg and Stikland Hospitals in the Western Cape Province, South Africa. The metabolic syndrome profiles of all 33 participants were compared at baseline and at point of relapse. All participants were given a monthly dose of an injectable antipsychotic, flupenthixol decanoate, which was gradually reduced until the participant relapsed or was off treatment. Adherence to treatment was guaranteed as all participants had to visit the healthcare facility to receive their injectable. Results: The majority of the participants were colored (75.8%). Most (64%) of the participants were overweight. The mean time to relapse was 39.2 weeks, and by week 32, almost half of the participants had relapsed. A significant change was observed for weight (p = 0.018), waist circumference (p = 0.006) and fasting glucose (p = 0.045). There were no significant changes in the lipid parameters following the antipsychotic dose reduction. Conclusion: Antipsychotic dose reduction resulted in weight loss; however, the majority of patients relapsed with some having important consequences. Further studies are needed to understand the dynamics of treatment discontinuation in schizophrenia patients; however, clinicians should closely monitor patients taking antipsychotics as metabolic syndrome negatively impacts on the patients’ quality of life.en_US
dc.language.isoenen_US
dc.subject.otherAntipsychotics.en_US
dc.subject.otherSchizophrenia.en_US
dc.subject.otherInjectable antipsychotic.en_US
dc.subject.otherMetabolic syndrome.en_US
dc.subject.otherFirst episode psychosis.en_US
dc.titleEffects of antipsychotic dose reduction on metabolic syndrome in patients with first episode psychosis treated with a long-acting injectable antipsychotic.en_US
dc.typeThesisen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record